DrFirst vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
E-prescribing, medication history, and patient safety platform processing hundreds of millions of Rx transactions annually. Rockville MD; founded 2000; embedded in hundreds of EHR and clinical workflow platforms;
About
DrFirst is a health IT company that has been at the forefront of e-prescribing and medication management since its founding in 2000. Headquartered in Rockville, Maryland, DrFirst provides e-prescribing for controlled substances (EPCS), medication history retrieval, clinical decision support, and patient medication adherence tools to hospitals, physician practices, long-term care facilities, and health IT vendors. The company processes hundreds of millions of prescription transactions annually and is embedded in a wide range of EHR and clinical workflow platforms through its APIs and SDK integrations.\n\nDrFirst's flagship EPCS solution was among the earliest to achieve DEA compliance for electronic prescribing of controlled substances, a capability that has become essential as regulatory requirements and clinical adoption have expanded across all states. The company's medication history service aggregates pharmacy and payer claims data to give providers a more complete view of a patient's actual medication use, supporting medication reconciliation at transitions of care and reducing adverse drug events. DrFirst also offers Backline, a secure clinical communication platform for care team messaging.\n\nDrFirst occupies a specialized but critical position in the health IT ecosystem, providing medication-related infrastructure that EHR vendors embed in their platforms rather than build independently. This embedded model gives DrFirst broad distribution across the provider market and creates sticky, long-term customer relationships. The company has invested in expanding its clinical intelligence capabilities, including AI-driven prior authorization for specialty medications and smart alerts that surface relevant clinical guidance at the point of prescribing.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.